Myasthenia gravis is a rare neuromuscular disorder characterized by weakness and fatigability
of ocular, bulbar, and extremity musculature. The specific aim of this study is to determine
if oral methotrexate is an effective therapy for myasthenia gravis (MG) patients who are
prednisone dependent. Patients will be randomized to receive either methotrexate or placebo
and those who are entered onto this trial will have symptoms and signs of the disease while
on prednisone therapy. The hypothesis is that adding methotrexate therapy in these patients
will improve the MG manifestations so that the prednisone dose can be reduced and clinical
measures of MG severity will improve.
Funding Source - FDA OOPD